RELATED CONTENT
NEWS
- US Capitol Capsule: Will Myriad BRCA case relieve biopharma's patent anxiety?
- US Capitol Capsule: Swimming the political sea with the FDA: A fine kettle of fish?
- New cloud of uncertainty for DNA patents, as SCOTUS takes up Myriad
- SCOTUS could strike an 'uneasy compromise' for Myriad

